| Abstract | In this double-blind study, 557 patients with lower respiratory tract infection were randomly assigned to receive amoxicillin/clavulanate orally either every 12 hours (875/125 mg) or every 8 hours (500/125 mg) for 7-15 days. For the 455 patients evaluable for clinical efficacy at the end of therapy, clinical success was similar in the two groups: 93% and 94% in the 12-hour and 8-hour groups, respectively (P = .42). Bacteriologic success at the end of therapy was also comparable: 97% and 91% in the 12-hour and 8-hour groups, respectively (P = .86). The occurrence of adverse events related to treatment was similar for the two groups, but fewer patients in the 12-hour group reported moderate or severe diarrhea. Amoxicillin/clavulanate (875/125 mg) given every 12 hours is as effective and safe as every-8-hours administration of the combination (500/125 mg) for the treatment of lower respiratory tract infection. |
| Authors | A D Calver, N S Walsh, P F Quinn, C Baran, V Lonergan, K P Singh, W S Orzolek
(Affiliation: West Vaal Hospital, Orkney, South Africa.)
|
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 24
Issue 4
Pg. 570-4
(Apr 1997)
ISSN: 1058-4838 UNITED STATES |
| PMID | 9145729
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Anti-Bacterial Agents
- Clavulanic Acids
- Penicillins
- Amoxicillin
- Clavulanic Acid
|
| Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Amoxicillin
(adverse effects, therapeutic use)
- Anti-Bacterial Agents
(adverse effects, therapeutic use)
- Bronchitis
(drug therapy, microbiology)
- Clavulanic Acid
- Clavulanic Acids
(adverse effects, therapeutic use)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- International Cooperation
- Male
- Middle Aged
- Penicillins
(adverse effects, therapeutic use)
- Pneumonia, Bacterial
(drug therapy, microbiology)
- Respiratory Tract Infections
(drug therapy, microbiology)
- Time Factors
- Treatment Outcome
|
